p53、PTEN和MMR在子宫内膜癌中的表达及关联
Expression and Association of p53, PTEN and MMR in Endometrial Carcinoma
DOI: 10.12677/ACM.2023.1361453, PDF,   
作者: 刘 铭, 袁 芳, 王 蓁*:青岛大学附属医院妇科,山东 青岛;林 慧:青岛市妇女儿童医院妇科,山东 青岛 ;董娴宁:青岛大学附属医院病理科,山东 青岛
关键词: 子宫内膜癌p53PTENMMREndometrial Cancer p53 PTEN MMR
摘要: 目的:旨在分析53抑癌基因(p53)、张力蛋白同源物(PTEN)及错配修复蛋白(MMR)在子宫内膜癌(EC)组织中的表达,并探讨三种因子与EC临床病理特征的关系。方法:采用免疫组化方法检测90例正常子宫内膜、90例子宫内膜癌组织中p53、PTEN及MMR的表达水平,并分析三者间及与各项临床病理参数的关系。结果:1) EC组p53野生型表达率53.3% (48/90)、PTEN阳性表达率44.4% (40/90),正常内膜组(NE组) 73.3% (66/90)、97.7% (88/90)低,P值分别为P = 0.005、P < 0.001,差异有统计学意义。2) 子宫内膜癌中p53及PTEN的表达与FIGO分期、组织学分级、深肌层浸润、脉管浸润、淋巴结转移有关,MMR表达与组织学分期有关。3) MSI与p53、PTEN的表达呈正相关(r = 0.213, P = 0.044; r = 0.209, P = 0.048),PTEN与p53表达也呈正相关(r = 0.523, P < 0.001)。结论:PTEN、p53的表达及MMR缺失与EC患者病情发生发展及预后存在相关性,且p53、PTEN、MMR的表达存在正相关关系。
Abstract: Objective: To analyze the expression of 53 tumor suppressor gene (p53), phosphatase and tensin homolog (PTEN) and mismatch repair protein (MMR) in endometrial carcinoma (EC) tissues, and to explore the relationship between these three factors and the clinicopathologic features of EC. Methods: Immunohistochemical methods were used to detect the expression levels of p53, PTEN and MMR in 90 cases of normal endometrial and 90 cases of endometrial cancer, and to analyze the relationship between the three and various clinicopathological parameters Results: 1) The wild type expression rate of p53 was 53.3% (48/90) in EC group, and the positive expression rate of PTEN was 44.4% (40/90), while the normal endometrial group (NE group) was 73.3% (66/90) and 97.7% (88/90) lower, with P = 0.005 and P < 0.001, respectively, indicating statistically significant differences. 2) The expression of p53 and PTEN in endometrial carcinoma is related to FIGO stage, histological grade, deep muscle invasion, vascular invasion and lymph node metastasis, and the ex-pression of MMR is related to histological stage. 3) MSI was positively correlated with the expression of p53 and PTEN (r = 0.213, P = 0.044; r = 0.209, P = 0.048), PTEN was also positively correlated with p53 expression (r = 0.523, P < 0.001). Conclusion: The expression of PTEN and p53 and the absence of MMR were correlated with the development and prognosis of EC patients, and the ex-pression of p53, PTEN and MMR was positively correlated.
文章引用:刘铭, 袁芳, 林慧, 董娴宁, 王蓁. p53、PTEN和MMR在子宫内膜癌中的表达及关联[J]. 临床医学进展, 2023, 13(6): 10376-10385. https://doi.org/10.12677/ACM.2023.1361453

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[3] Jiang, X.Y., Tang, H.J. and Chen, T.H. (2018) Epidemiology of Gyneco-logic Cancers in China. Journal of Gynecologic Oncology, 29, e7. [Google Scholar] [CrossRef] [PubMed]
[4] Katz, M.S., Smith, L. and Simcock, R. (2018) Treatment Toxicity in Endometrial Cancer: Can We Identify and Manage It Bet-ter? The Lancet Oncology, 19, 602. [Google Scholar] [CrossRef
[5] Meyer, L.A., Bohlke, K. and Wright, A.A. (2016) Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncol-ogy Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. Journal of Oncology Practice, 12, 182-185. [Google Scholar] [CrossRef
[6] Bestvina, C.M. and Fleming, G.F. (2016) Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. The Oncolo-gist, 21, 1250-1259. [Google Scholar] [CrossRef] [PubMed]
[7] de Haydu, C., Black, J.D., Schwab, C.L., English, D.P. and Santin, A.D. (2016) An Update on the Current Pharmacotherapy for Endometrial Cancer. Expert Opinion on Pharmacotherapy, 17, 489-499. [Google Scholar] [CrossRef] [PubMed]
[8] 王辉, 韩琛, 董新茜, 等. 子宫内膜癌组织中Ki-67、Bcl-2、p53蛋白表达变化及意义[J]. 山东医药, 2018, 58(21): 21-24.
[9] Tao, Y. and Liang, B. (2020) PTEN Mutation: A Potential Prognostic Factor Associated with Immune Infiltration in Endometrial Carcinoma. Pathology—Research and Practice, 216, Article ID: 152943. [Google Scholar] [CrossRef] [PubMed]
[10] Hussain, S.P., Amstad, P., He, P., et al. (2004) P53-Induced Up-Regulation of MnSOD and GPx but Not Catalase Increases Oxidative Stress and Apoptosis. Cancer Research, 64, 2350-2356. [Google Scholar] [CrossRef
[11] Chio, I.I.C. and Tuveson, D.A. (2017) ROS in Cancer: The Burning Question. Trends in Molecular Medicine, 23, 411-429. [Google Scholar] [CrossRef] [PubMed]
[12] Zheng, W., Chen, Q., Wang, C., et al. (2020) Inhibition of Ca-thepsin D (CTSD) Enhances Radiosensitivity of Glioblastoma Cells by Attenuating Autophagy. Molecular Carcinogene-sis, 59, 651-660. [Google Scholar] [CrossRef] [PubMed]
[13] Ikeguchi, M., Sakatani, T., Ueta, T., et al. (2002) Correla-tion between Cathepsin D Expression and P53 Protein Nuclear Accumulation in Oesophageal Squamous Cell Carcinoma. Journal of Clinical Pathology, 55, 121-126. [Google Scholar] [CrossRef] [PubMed]
[14] Martínez, P.T., Navajas, P.L. and Lietha, D. (2020) FAK Structure and Regulation by Membrane Interactions and Force in Focal Adhesions. Biomolecules, 10, Article No. 179. [Google Scholar] [CrossRef] [PubMed]
[15] Alfieri, R., Giovannetti, E., Bonelli, M. and Cavazzoni, A. (2017) New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhe-sion Kinase Pathway. Frontiers in Oncology, 7, Article 170. [Google Scholar] [CrossRef] [PubMed]
[16] 何亚, 胡元晶. p53和MMR联合检测在子宫内膜癌预后判断中的作用[J]. 现代妇产科进展, 2019, 28(9): 651-656.
[17] 郭骏辉, 刘冬梅, 乔爱琪, 等. 错配修复蛋白表达与子宫内膜癌临床病理特征的关系[J]. 肿瘤研究与临床, 2017, 29(10): 649-652+666.
[18] 郭璐璐, 王翔宇, 付广明, 等. 不同错配修复蛋白检测组合对子宫内膜癌患者预后判断的价值及意义[J]. 精准医学杂志, 2022, 37(4): 365-369.
[19] 晋薇, 马亚琪, 王昀, 刘爱军. 错配修复基因MLH1、MSH2、MSH6及PMS2在子宫内膜癌中的表达及临床意义[J]. 诊断病理学杂志, 2018, 25(5): 335-339.
[20] Cao. Y., Ye, Q., Zhuang, M., et al. (2017) Ginsenoside Rg3 Inhibits Angiogenesis in a Rat Model of Endometriosis through the VEGFR-2-Mediated PI3K/Akt/mTOR Signaling Pathway. PLOS ONE, 12, e0186520. [Google Scholar] [CrossRef] [PubMed]
[21] Álvarez-Garcia, V., Tawil, Y., Wise, H.M. and Leslie, N.R. (2019) Mechanisms of PTEN Loss in Cancer: It’s All about Diversity. Seminars in Cancer Biology, 59, 66-79. [Google Scholar] [CrossRef] [PubMed]